National Institute of Mental Health
Division of US Department of Health and Human Services
Latest From National Institute of Mental Health
The firm’s $260m Series D is the largest ever for biopharma in China and one of the biggest of the year worldwide; other notable financings go to Biohaven, Kymab and Magenta. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October through early December.
The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.
Akili Interactive plans rigorous clinical trials for its mobile gaming app “Project EVO,” amassing empirical observations in the context of the mainstream medical enterprise, where developers believe it will be effective as both a clinical tool and a therapeutic.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.